WuXi Biologics Collabs with HanchorBio on Next-Generation Fusion Protein Pipelines

HanchorBio, a clinical-stage biotechnology company, and WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), established a strategic collaboration for the development and manufacturing of next-generation bi-functional and multi-functional fusion protein programs from HanchorBio’s pipeline according to a WuXi Biologics press release.¹ Focusing on multiple assets derived from a proprietary Fc-Based Designer Biologics (FBDB) platform, this platform is designed to activate both innate and adaptive immune pathways to address unmet needs in oncology and autoimmune diseases.

Why is technical scalability vital for complex fusion proteins?

In the specialized field of fusion protein development, maintaining execution efficiency in Chemistry, Manufacturing, and Controls (CMC) is essential for successful clinical translation. The collaboration is structured to support the transition of molecules from HanchorBio’s FBDB platform into scalable global clinical development. Under the terms of the agreement, the partnership provides end-to-end services including cell line development, drug product formulation, and Good Manufacturing Practice (GMP) manufacturing.¹ The robustness of these processes is critical for managing capital efficiency and maintaining flexibility across multiple clinical assets.

Dr. Scott Liu, founder, chairman, and chief executive officer of HanchorBio, commented in the press release¹, “This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics’ proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline.”

How do integrated platforms address development timelines for novel modalities?

The manufacturing landscape is increasingly dominated by complex modalities. As of late 2025, approximately 60% of the 945 integrated projects supported by WuXi Biologics involved bi-specific antibodies, multi-specific antibodies, and fusion proteins.¹ To manage this complexity, the industry relies on integrated platforms that offer specialized technologies, such as targeted integration-based cell line development and high-throughput formulation tools designed to enhance quality and scalability. These technical capabilities, combined with a workforce of over 12,000 employees and a global quality system, are intended to shorten the journey from concept to commercialization.

Dr. Chris Chen, chief executive officer of WuXi Biologics, said: “We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics’ comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio’s innovative bi-/multi-fusion proteins and help bring transformative therapies to patients worldwide.”¹

This alignment of discovery-stage innovation with globally compliant GMP manufacturing execution reflects a broader industry strategy to advance complex, platform-derived pipelines with increased speed and reliability.¹ By utilizing a single-source CRDMO model, the partnership seeks to streamline the technical requirements of CMC development while supporting the expansion of innovative immunotherapy portfolios.

How else is WuXi Biologics bolstering its manufacturing capabilities?

Beyond the initial focus on platform-driven innovation, the capacity to meet diverse international standards is a prerequisite for global commercial success. This is evidenced by recent regulatory milestones, such as the UK MHRA granting GMP certifications for commercial manufacturing of an ophthalmic biologic to WuXi Biologics.²

Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, noted in a press release, “we are delighted to receive GMP certification from MHRA, a testament to our steadfast commitment to the highest global quality standards. Quality is fundamental to ensuring safety and efficacy. Maintaining a 100% success rate for regulatory inspections reflects our relentless pursuit of excellence and efficiency in commercial manufacturing.”²

WuXi Biologics continues to maintain a strong regulatory track record, including 46 successful inspections by late 2025,² providing the reliability necessary to navigate complex global supply chains. By integrating high-capacity manufacturing with specialized delivery technologies and a focus on green technology innovation, developers can better ensure that platform-derived innovations reach patients with speed and compliance.

References:

1. Wu Xi Biologics. WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline. Press Release. Jan 26, 2026.
2. Wu Xi Biologics. WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic. Press Release. Jan 13, 2026.